Rathbones Group PLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 1.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,499 shares of the company’s stock after acquiring an additional 1,958 shares during the quarter. Rathbones Group PLC owned 0.17% of IDEXX Laboratories worth $70,756,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in IDEXX Laboratories in the 2nd quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IDEXX Laboratories by 4.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after buying an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after buying an additional 288,471 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after buying an additional 197,808 shares in the last quarter. Finally, William Blair Investment Management LLC lifted its position in shares of IDEXX Laboratories by 2.7% during the 3rd quarter. William Blair Investment Management LLC now owns 306,107 shares of the company’s stock worth $159,846,000 after buying an additional 7,953 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at IDEXX Laboratories
In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Lane sold 3,979 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $688.64, for a total value of $2,740,098.56. Following the transaction, the executive vice president directly owned 4,076 shares in the company, valued at $2,806,896.64. This represents a 49.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 41,428 shares of company stock valued at $28,567,934 in the last quarter. Insiders own 0.79% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on IDXX shares. Jefferies Financial Group reduced their target price on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a report on Tuesday, October 20th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Morgan Stanley boosted their price objective on IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday, October 16th. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $717.27.
IDEXX Laboratories Stock Down 1.9%
IDEXX Laboratories stock opened at $676.21 on Friday. The firm has a 50 day moving average price of $579.87 and a 200-day moving average price of $574.26. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a market capitalization of $53.28 billion, a P/E ratio of 45.60 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter in the previous year, the firm posted $3.22 EPS. IDEXX Laboratories’s revenue was up 9.9% on a year-over-year basis. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
